Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anna Capasso

Showing results (141-150 of 170) with videos related to

Pageof 17
Sort By:
Oncotarget|April 13, 2016
The novel tankyrase inhibitor (AZ1366) enhances irinotecan activity in tumors that exhibit elevated tankyrase and irinotecan resistanceKevin S Quackenbush, Stacey Bagby, Wai Meng Tai, et al.
ESMO Open|December 7, 2017
Clinical outcome and molecular characterisation of chemorefractory metastatic colorectal cancer patients with long-term efficacy of regorafenib treatmentErika Martinelli, Vincenzo Sforza, Claudia Cardone, et al.
Peptides|May 25, 2010
Sexual dimorphic evolution of metabolic programming in non-genetic non-alimentary mild metabolic syndrome model in mice depends on feed-back mechanisms integrity for pro-opiomelanocortin-derived endogenous substancesStefano Loizzo, Stefano Vella, Alberto Loizzo, et al.
Molecular Cancer Therapeutics|July 21, 2018
Cabozantinib Exhibits Potent Antitumor Activity in Colorectal Cancer Patient-Derived Tumor Xenograft Models via Autophagy and Signaling MechanismsAaron J Scott, John J Arcaroli, Stacey M Bagby, et al.
Breast Cancer Research : BCR|August 4, 2018
A phase II clinical trial of the Aurora and angiogenic kinase inhibitor ENMD-2076 for previously treated, advanced, or metastatic triple-negative breast cancerJennifer R Diamond, S G Eckhardt, Todd M Pitts, et al.
Journal of Translational Medicine|October 4, 2025
MicroRNA signatures of cancer risk in kidney transplant patients: insights from the COMETA studyMariadelina Simeoni, Rossella Tufano, Valeria Grandinetti, et al.
Neuromuscular Disorders : NMD|August 23, 2023
Patient reported outcome measure for upper limb in Duchenne muscular dystrophy: correlation with PUL2.0Gianpaolo Cicala, Marika Pane, Giorgia Coratti, et al.
European Journal of Pediatrics|May 6, 2022
Neurological assessment of newborns with spinal muscular atrophy identified through neonatal screeningMarika Pane, Maria Alice Donati, Costanza Cutrona, et al.
Molecular Cancer Therapeutics|September 7, 2019
First-in-Class Phosphorylated-p68 Inhibitor RX-5902 Inhibits β-Catenin Signaling and Demonstrates Antitumor Activity in Triple-Negative Breast CancerAnna Capasso, Stacey M Bagby, Kyrie L Dailey, et al.
Annals of Clinical and Translational Neurology|May 14, 2025
Myostatin Levels in SMA Following Disease-Modifying Treatments: A Multi-Center StudyFiorella Piemonte, Sara Petrillo, Anna Capasso, et al.
Pageof 17

Showing results (141-150 of 170) with videos related to

Sort By:
Pageof 17
Oncotarget|April 13, 2016
The novel tankyrase inhibitor (AZ1366) enhances irinotecan activity in tumors that exhibit elevated tankyrase and irinotecan resistanceKevin S Quackenbush, Stacey Bagby, Wai Meng Tai, et al.
ESMO Open|December 7, 2017
Clinical outcome and molecular characterisation of chemorefractory metastatic colorectal cancer patients with long-term efficacy of regorafenib treatmentErika Martinelli, Vincenzo Sforza, Claudia Cardone, et al.
Peptides|May 25, 2010
Sexual dimorphic evolution of metabolic programming in non-genetic non-alimentary mild metabolic syndrome model in mice depends on feed-back mechanisms integrity for pro-opiomelanocortin-derived endogenous substancesStefano Loizzo, Stefano Vella, Alberto Loizzo, et al.
Molecular Cancer Therapeutics|July 21, 2018
Cabozantinib Exhibits Potent Antitumor Activity in Colorectal Cancer Patient-Derived Tumor Xenograft Models via Autophagy and Signaling MechanismsAaron J Scott, John J Arcaroli, Stacey M Bagby, et al.
Breast Cancer Research : BCR|August 4, 2018
A phase II clinical trial of the Aurora and angiogenic kinase inhibitor ENMD-2076 for previously treated, advanced, or metastatic triple-negative breast cancerJennifer R Diamond, S G Eckhardt, Todd M Pitts, et al.
Journal of Translational Medicine|October 4, 2025
MicroRNA signatures of cancer risk in kidney transplant patients: insights from the COMETA studyMariadelina Simeoni, Rossella Tufano, Valeria Grandinetti, et al.
Neuromuscular Disorders : NMD|August 23, 2023
Patient reported outcome measure for upper limb in Duchenne muscular dystrophy: correlation with PUL2.0Gianpaolo Cicala, Marika Pane, Giorgia Coratti, et al.
European Journal of Pediatrics|May 6, 2022
Neurological assessment of newborns with spinal muscular atrophy identified through neonatal screeningMarika Pane, Maria Alice Donati, Costanza Cutrona, et al.
Molecular Cancer Therapeutics|September 7, 2019
First-in-Class Phosphorylated-p68 Inhibitor RX-5902 Inhibits β-Catenin Signaling and Demonstrates Antitumor Activity in Triple-Negative Breast CancerAnna Capasso, Stacey M Bagby, Kyrie L Dailey, et al.
Annals of Clinical and Translational Neurology|May 14, 2025
Myostatin Levels in SMA Following Disease-Modifying Treatments: A Multi-Center StudyFiorella Piemonte, Sara Petrillo, Anna Capasso, et al.
Pageof 17